RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516063-89-00

Acronym

RMC-6236-302

Enrollment

136

Registered

2024-12-13

Start date

2025-04-10

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Brief summary

PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per RECIST v1.1 and as assessed by BICR. OS is defined as the time from randomization until death from any cause.

Interventions

DRUGPACLITAXEL ALBUMIN-BOUND

DRUGOXALIPLATIN

DRUGGEMCITABINE HYDROCHLORIDE

DRUGDARAXONRASIB (RMC-6236)

DRUGFOLINIC ACID

DRUGFLUOROURACIL

DRUGIRINOTECAN

DRUGIRINOTECAN HYDROCHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per RECIST v1.1 and as assessed by BICR. OS is defined as the time from randomization until death from any cause.	—

Countries

France, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026